BIOMARKERS

Learn about biomarker research model systems and tools and how they can accelerate patient treatment and drug development

Biomarkers are increasingly being utilized in clinical diagnosis, treatment, as well as in drug discovery and development. This course covers major theoretical concepts and practical issues involved in identifying and applying biomarkers in disease classification and patient treatment decisions in the clinic and drug development.

OCT 18–NOV 14, 2021
Mondays, Wednesdays and Thursdays
3:00–5:00 PM PST
Live Online using Zoom Conference Technology

INFORMATION
Andrea Laserna, Program Manager
alaserna@ucsd.edu | 858-534-6648

TOPICS WILL INCLUDE
- Biomarker requirements, classification and criteria for evaluating potential markers
- The practice of sample collection and quality control for a biomarker study in conjunction with epidemiological studies, including design, analysis and more
- Ethical and legal concerns
- Biomarker analyses tools including flow cytometry, digital pathology, ligand binding, DNA arrays, gene expression arrays and proteomics
- Biomarkers in diseases, including cancer and autoimmune disease, such as rheumatoid arthritis
- Biomarkers in Drug Discovery in animal models, in vitro diagnostics and surrogate and endpoint biomarker.

SPEAKERS

Jelveh Lameh, Ph.D.
Executive Director, Head of Operations and Regulatory Affairs, Navigate BioPharma Services Inc.

Hua Gong, Ph.D.
COO and Head of Precision Medicine, Adagene

Nathan Riccitelli, Ph.D.
Manager, Molecular Assay Development, Navigate BioPharma Services

Naveen Dakappagari, Ph.D.
Sr. Director, Head, Protein Biomarker Solutions, Navigate BioPharma Services Inc.

Chad Ray, Ph.D.
Senior Scientific Director,
Global Therapeutics Research Pharmacokinetics, Dynamics, Metabolism, Zoetis